Swedish biopharmaceutical company Sobi (STO: SOBI), which focuses on rare diseases, said on Tuesday that the European Commission has approved Tryngolza (olezarsen) for adults with severe hypertriglyceridaemia (sHTG).
It is the first and only RNA-targeted therapy authorised in the EU for this group.
The decision follows an early positive opinion from the Committee for Medicinal Products for Human Use in October, and widens the existing marketing authorisation for Tryngolza, which already covers familial chylomicronaemia syndrome.
Approval rests on the Phase 3 CORE and CORE2 studies. In patients with baseline triglyceride levels of at least 880 mg/dL, Tryngolza cut triglycerides by up to 73% at six months versus placebo (p
Aelis Farma announces receipt of second positive safety recommendation for Down syndrome trial
Specialised Therapeutics' YONDELIS sarcoma therapy approved in Thailand
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Eisai launches subcutaneous Leqembi Pen in Japan for early Alzheimer's disease
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme